Peanut allergy

DBV Technologies to Participate in Upcoming AAAAI 2022 Congress

Retrieved on: 
Tuesday, February 22, 2022
Aurora, Risk, DBV Technologies, AAAAI, Ticker, Immune system, American Academy, Children's Hospital Colorado, American Academy of Allergy, Asthma, and Immunology, University, COVID-19, Safety data sheet, Company, Press release, Clinical trial, Sale, Safety, Peanut allergy, Allergy, Ageing, United, Skin, Adrenaline, ISIN, Asthma, Patient, Nasdaq, DBV, U.S. Securities and Exchange Commission, Immunotherapy, Vanderbilt University Medical Center, Research, University of Colorado, Pharmaceutical industry, Euronext Paris, Euronext

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Scientific meeting, February 24 February 28, 2022.

Key Points: 
  • DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Scientific meeting, February 24 February 28, 2022.
  • The data that we are showcasing at AAAAI this year highlight the safety and tolerability potential of epicutaneous immunotherapy and the Viaskin platform, said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies.
  • DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY.
  • Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy

Retrieved on: 
Tuesday, February 8, 2022
GLOBE, Maintenance, Growth, Cohort, Anaphylaxis, Peanut allergy, Food allergy, Medical college, IND, Therapy, Augusta University, Patient, Safety, Trial of the century, Immunotherapy, CEO, Food, Pharmaceutical industry, Pediatrics

NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy. INT301 is a novel peanut desensitization immunotherapy formulated as a fully-functioning toothpaste and conveniently administered during a patient’s daily toothbrushing routine.

Key Points: 
  • After acceptance of our IND for INT301, we launched and completed Cohort 1 of our Phase 1 OMEGA Clinical Study last year in adults with peanut allergy.
  • While the study remains blinded, there were no significant adverse events in any patient, said Michael Nelson, CEO, Intrommune Therapeutics.
  • Intrommune Therapeutics Phase 1 OMEGA Clinical Study is a randomized, double-blind, placebo-controlled study that enrolled adults with peanut allergy in a 3:1 ratio to receive either an escalating dose of INT301 or placebo.
  • The study groups are blinded to the investigator, participants, and the Intrommune study team.

Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut

Retrieved on: 
Wednesday, January 26, 2022
Histamine, Food allergy, Immunoglobulin E, AIM, The Journal of Allergy and Clinical Immunology, CEO, Allergy, Adult, Ara, Imperial College London, Prevalence, IND, The New England Journal of Medicine, Risk, VLP, Peanut allergy, Technology, Therapy, Population, T helper cell, Western world, TH1, PROTECT, Journal, Patient, JAMA, FDA, Pharmaceutical industry, Vaccine, Medical device, EU

The potential of an effective short-course peanut allergy vaccine represents a significant opportunity in the $8 billion worldwide food allergy market1.

Key Points: 
  • The potential of an effective short-course peanut allergy vaccine represents a significant opportunity in the $8 billion worldwide food allergy market1.
  • Peanut allergy is one of the most common types of food allergy and its symptoms can range from mild to severe and life-threatening.
  • Manuel Llobet, CEO of Allergy Therapeutics,stated: We have achieved a key milestone with the FDAs clearance of our IND application and look forward to advancing our innovative peanut allergy vaccine candidate into the clinic.
  • VLP Peanut is being developed as a novel VLP-based therapy for the treatment of peanut allergy.

Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships

Retrieved on: 
Tuesday, December 21, 2021
Science, GLOBE, Degenerative disease, Therapy, Entrepreneurship, Health, The Forsyth Institute, Strategic management, University of Navarra, CEO, MBA, Allergy, Eosinophilic esophagitis, Food allergy, Trilla, Universidad, Food, MD, Peanut allergy, Mentorship, Anaphylaxis, Immunotherapy, Patient, Knowledge, Pharmaceutical industry, Management, Vaccine, Partnership

Dr Trilla will apply the knowledge gained from his experience collaborating on over 160 life science partnerships to oversee corporate strategy, business partnerships and lead Intrommune through our business planning process.

Key Points: 
  • Dr Trilla will apply the knowledge gained from his experience collaborating on over 160 life science partnerships to oversee corporate strategy, business partnerships and lead Intrommune through our business planning process.
  • I am confident that my background as a licensed physician and global entrepreneur distinguishes me as an ideal leader for Intrommune, said Sergi Trilla, MD, MBA, Director of Corporate Strategy & Partnerships, Intrommune.
  • My decades of life science business experience will help advance Intrommune and its OMIT food allergy technology platform.
  • My expertise in international healthcare business also provides a perspective to help Intrommune in its global product and corporate development and partnerships, added Trilla.

DBV Technologies Provides Update on Investigational Viaskin™ Peanut

Retrieved on: 
Monday, December 20, 2021
EMA, MAA, ID, Adult, Skin, Review, ISIN, Communication, Ticker, Licensure, FDA, Trial of the century, Union, Physician, Press release, European Directive on Traditional Herbal Medicinal Products, IFU, CHMP, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Food, DBV Technologies, Marketing, Safety, Research, AMF, Peanut allergy, Use, U.S. Securities and Exchange Commission, DBV, CVP, News, Company, Most, Nasdaq, SEC, European Medicines Agency, Population, Immune system, Sale, Peanut, Patient, Immunotherapy, Pharmaceutical industry, Euronext, Euronext Paris

The Company also issued an update on the Marketing Authorization Application for Viaskin Peanut with the European Medicines Agency (EMA).

Key Points: 
  • The Company also issued an update on the Marketing Authorization Application for Viaskin Peanut with the European Medicines Agency (EMA).
  • The study will feature the modified Viaskin Peanut (mVP) patch, which is circular in shape and approximately 50% larger than the current Viaskin Peanut (cVP) patch.
  • DBV is confident that a new, Phase 3 pivotal study generating a robust data set is the best way to support the development of Viaskin Peanut, said Daniel Tasse, Chief Executive Officer, DBV Technologies.
  • DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy.

New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma

Retrieved on: 
Wednesday, December 8, 2021
Peanut allergy, U.S. Securities and Exchange Commission, Casirivimab/imdevimab, Atopic dermatitis, Twitter, Forward-looking statement, Company, Regulation, Research, Pharmacy, SEC, Medicare, Allergic bronchopulmonary aspergillosis, Alirocumab, Safety, Annual report, Forest Law Enforcement and Governance Program, Private Securities Litigation Reform Act, Form 20-F, Privacy, AMF, Patient, Product, Nature, Sinusitis, Chronic obstructive pulmonary disease, Eosinophilic esophagitis, Form 10-K, Polyp (medicine), Government, Prurigo nodularis, COVID-19, Ageing, Patent, Intellectual property, Marketing, Health, Judgement, Social media, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry

These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product.

Key Points: 
  • These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product.
  • Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions.
  • Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
  • Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed ( http://twitter.com/regeneron ).

Global Peanut Allergy Clinical Trials Review, H2 2021 Report - ResearchAndMarkets.com

Retrieved on: 
Friday, October 29, 2021
Pharmaceutical, Health, Clinical Trials, News, G7, Decision-making, Clinical trial, Trial, Peanut allergy, Pharmaceutical industry

The "Peanut Allergy - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peanut Allergy - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Peanut Allergy - Global Clinical Trials Review, H2, 2021" provides an overview of the Peanut Allergy Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Peanut Allergy.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Peanut Allergy to Immunology Clinical Trials

COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy

Retrieved on: 
Tuesday, October 19, 2021
Judy, Allergy, The Journal of Allergy and Clinical Immunology, Biotechnology, Food allergy, Immune system, Degenerative disease, Nanoparticle, Asthma, Journal, Risk, Technology, Takeda Pharmaceutical Company, Autoimmunity, Lists of diseases, California, Allergen, Autoimmune disease, Medical research, Principal investigator, Peanut allergy, Research, Stanford University, Entrepreneurship, CEO, Safety, Patient, Fatality, Epitope, Virginia Mason Medical Center, Immunodeficiency, Company, Trial of the century, Pharmaceutical industry, Vaccine, Dairy product

"This study will produce important clinical data to guide COUR's future and continues to demonstrate our commitment to our patients."

Key Points: 
  • "This study will produce important clinical data to guide COUR's future and continues to demonstrate our commitment to our patients."
  • A recent study in the Journal of Allergy and Clinical Immunology found that as many as 4.6 million U.S. adults are allergic to peanuts.
  • "Medical Research of Arizona, the research division of Allergy, Asthma & Immunology Associates, is excited to have enrolledand dosedthe first patient in the CNP-201-5.001 peanut allergy clinical study.
  • "Peanut allergy is a Th2 cell mediated immune response against peanut protein epitopes.

Intrommune Participates in the Forsyth dentech 2021 Conference

Retrieved on: 
Wednesday, September 22, 2021
Therapy, Poster, Â, Allergy, Anaphylaxis, Peanut, FDA, Patient, MD, The Forsyth Institute, Immunotherapy, CEO, Dentistry, Food allergy, Technology, MBA, Research, Peanut allergy, Food, Doctor of Philosophy, Industry, GLOBE, Pharmaceutical industry, Vaccine

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will present at the prestigious Forsyth dentech 2021 oral health technology conference on Thursday, September 23, 2021.

Key Points: 
  • NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will present at the prestigious Forsyth dentech 2021 oral health technology conference on Thursday, September 23, 2021.
  • Forsyth dentech 2021 is the worlds leading conference focused specifically on dentistry and oral health technology development.
  • To register for the event please visit: http://forsyth.org/dentech2021/
    We are very excited to be selected as one of only 18 companies for a podium presentation at the 2021 Forsyth dentech 2021 meeting, said Michael Nelson, CEO, Intrommune.
  • It is a privilege to invite Intrommune to participate in our 2021 dentech conference, said Dr. Wenyuan Shi, PhD, Chief Executive Officer & Chief Science Officer of The Forsyth Institute.

Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board

Retrieved on: 
Tuesday, September 21, 2021
Therapy, Compliance, Thomas, Postgraduate training in general dentistry, Degenerative disease, Allergy, Anaphylaxis, Patient, Population, Chief Dental Officer (Canada), Dental Materials, Esophagus, Aesthetics, American Board of Commissioners for Foreign Missions, Compendium, Immunotherapy, CEO, Academy, Medicare Physician Group Practice (PGP) Demonstration, Stomach, Food allergy, Journal, Technology, Cosmetic dentistry, Academy of General Dentistry, Peanut allergy, Mouth, Food, Allergen, Private practice, Eosinophilic esophagitis, GLOBE, Pharmaceutical industry, Vaccine, Dentistry

“Intrommune’s OMIT technology is a very elegant immunotherapy platform for the treatment of peanut allergy – it’s easy to use and has the potential to transform millions of lives,” said Gerard Kugel, D.M.D., M.S., Ph.D., Trinity Dental Boston, Fellow in the Academy of General Dentistry and the Academy of Dental Materials. “Treatment regimens that are too complicated suffer from lack of adherence, especially in a pediatric patient population. A toothpaste makes adherence so easy -- resulting in a much higher compliance rate.”

Key Points: 
  • The Companys oral mucosal immunotherapy (OMIT) platform is based on the well-accepted principles of allergy immunotherapy.
  • Considering that our lead product will be delivered via an innovative toothpaste, our relationship with Dr. Kugel will prove extremely valuable, said Michael Nelson, CEO, Intrommune Therapeutics.
  • INT301 immunotherapy will be a toothpaste replacement, providing a simple daily administration which supports long term use and adherence.
  • He belongs to scores of professional societies and has written and contributed to hundreds of scientific and clinical publications.